9.13 0.00 (0.00%)
After hours: 4:54PM EDT
|Bid||9.13 x 900|
|Ask||9.49 x 2200|
|Day's Range||8.88 - 9.50|
|52 Week Range||8.20 - 24.48|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.70|
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (AMRX). For many years, the Company, (formerly Impax Laboratories Inc.), which develops, manufactures, and markets bioequivalent, generic, pharmaceutical products, has been embroiled in investigations and litigation by state and federal authorities and relating to claims that it colluded with other competitor companies in a price-fixing scheme resulting in exponential price increases of certain products. The Company has been sued in a securities class action lawsuit for failing to disclose material information to shareholders, violating federal securities laws, which is ongoing.
Amneal Pharmaceuticals, Inc. today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m.
NEW YORK , May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") ...
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 2.66%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Bridgewater, New Jersey-based company said it had a loss of 37 cents per share. Earnings, adjusted for one-time gains and costs, were 14 cents per share. The results missed Wall Street expectations. ...
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Amneal Pharmaceuticals, Inc. will release its first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on May 9, 2019.
Amneal Pharmaceuticals, Inc. (AMRX), today announced that the company has appointed Pradeep Bhadauria as Chief Scientific Officer (CSO), effective immediately. Pradeep brings significant R&D expertise to Amneal, including more than 20 years leading the development capabilities for several leading generic and specialty pharmaceutical companies.
BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that operates the company's commercial operations in the United Kingdom. "We believe that the value created by our commercial operations in the UK will be better maximized by Zentiva, which will gain additional products and enhanced competitive market share position as a result of this transaction," said Rob Stewart, President and CEO of Amneal.
President and CEO of Amneal Pharmaceuticals Inc (NYSE:AMRX) Robert A Stewart bought 17,000 shares of AMRX on 03/12/2019 at an average price of $11.92 a share.
BRIDGEWATER, N.J., March 12, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has launched its generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company received FDA approval of its Rivastigmine Transdermal System in January 2019, and has received final approval on 10 Abbreviated New Drug Applications this year. "We are pleased to have received approval on and launched the company's first transdermal product, which demonstrates our commitment to develop and bring to market complex generic products," said Rob Stewart, President and CEO of Amneal.
BRIDGEWATER, N.J. , March 6, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Barclays Global Healthcare ...
Amneal Pharmaceuticals Inc (NYSE:AMRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
‒ Q4 2018 Net Revenue of $498 Million ; GAAP Loss per share of $0.07 ; Combined Adjusted Diluted EPS(1) of $0.33 ‒ ‒ Full Year 2018 Net Revenue of $1.66 Billion ; GAAP Loss per share of $0.16 ; Combined ...
Genentech bought InterMune and the Brisbane company's idiopathic pulmonary fibrosis drug Esbriet for more than $8 billion in fall 2014. Now it faces pressure from more than a dozen generic drug makers.
- Announces 2019 Quarterly Earnings Dates - BRIDGEWATER, N.J. , Jan. 24, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter ...
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) P/E ratio and reflect Read More...
BRIDGEWATER, N.J., Jan. 22, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX) today announced that it has appointed Todd P. Branning as Senior Vice President and Chief Financial Officer, effective today. Mr. Branning will be responsible for leading Amneal's global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Corporate Communications, and Information Technology.
BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has received FDA approval for a generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company is planning to commercialize its Rivastigmine Transdermal System shortly. "We are pleased to receive approval on the company's first transdermal product, which demonstrates our commitment to develop and bring to market complex generic products," said Rob Stewart, President and CEO of Amneal.